• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Navidea Biopharmaceuticals Inc (NY: NAVB )

    N/A UNCHANGED
    Last Price Updated: 8:00 PM EDT, Oct 5, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Navidea Biopharmaceuticals Inc

    < Previous 1 2 3 4 5 6 Next >
    The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
    Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... 
    Via Benzinga
    Navidea Biopharmaceuticals to Host Fourth Quarter 2021 Earnings Conference Call and Business Update
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Shares Jump On Research Pact For Tc99m Tilmanocept As Biomarker In Brain Cancer
    Navidea Biopharmaceuticals Inc (NYSE: NAVB) has  
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
    On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
    Via Benzinga
    47 Biggest Movers From Yesterday
    Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
    Via Benzinga
    Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, trader! It's time to kick off another day with a dive into the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday! 
    Via InvestorPlace
    The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
    Via Benzinga
    Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Shares Gain After Terminating Stock Purchase Agreement
    Navidea Biopharmaceuticals Inc (NYSE: NAVB) has terminated the Stock Purchase Agreement executed on August 30, 2020. The investors agreed to purchase up to $25.0... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Good morning, trader! We're getting right into the swing of things with a breakdown of the biggest pre-market stock movers for Thursday! 
    Via InvestorPlace
    18 Stocks Moving in Thursday's Pre-Market Session
    Gainers Calliditas Therapeutics AB (NASDAQ: CALT) rose 36.5% to $25.45 in pre-market trading after the company announced it was granted by the FDA accelerated approval of TARPEYO... 
    Via Benzinga
    Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Terminates Stock Purchase Agreement
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
    Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
    Via Benzinga
    Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
    Via Benzinga
    Exposures COVID-19
    Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Appoints Thomas Forest Farb-Horch and Agnieszka Winkler to the Board of Directors
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Looking Into Navidea Biopharmaceutical's Return On Capital Employed
    According to Benzinga Pro data, during Q2, Navidea Biopharmaceutical (AMEX:NAVB) posted sales of $261.05 thousand. Earnings were up 19.83%, but Navidea Biopharmaceutical still... 
    Via Benzinga
    Navidea Biopharmaceuticals Appoints Michel Mikhail, Ph.D. as Chief Regulatory Officer
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    4 Penny Stocks Insiders Are Buying
    When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
    Via Benzinga
    Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results
    From Navidea Biopharmaceuticals, Inc.
    Via Business Wire
    The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.